Korean Post-marketing Surveillance for Reyataz.

Trial Profile

Korean Post-marketing Surveillance for Reyataz.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs Atazanavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 20 Apr 2016 Status changed from recruiting to completed.
    • 08 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
    • 08 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top